Treatment of murine myeloid leukemia by aclacinomycin-A based on the dynamics of leukemic colony forming unit and normal hematopoietic stem cells.
D015250:Aclarubicin; D000328:Adult; D000818:Animals; D002471:Cell Transformation, Neoplastic; D003114:Colony-Forming Units Assay; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007942:Leukemia, Experimental / Q000097:blood / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009279:Naphthacenes / Q000627:therapeutic use
D009279:Naphthacenes; D015250:Aclarubicin